Phathom Pharmaceuticals
Edit info- Founded: 2019
- Location: Menlo Park, CA
- Employee range: 50 - 200
- Clinical stage: COM
- Therapy area: H. pylori infection
- Drug types: INF, GI, PED
- Lead product: Voquezna (Vonoprazan)
- Funding: $150M stock May 2023; $182M IPO Oct 2019; $90M May 2019
- Investors: Frazier Healthcare Partners, Medicxi, RA Capital Management, Abingworth
phathompharma.com linkedin.com job board
Business:
Novel treatments for gastrointestinal diseases and disorders
Drug notes:
Also NDA errosive GERD, heartburn, Clin3 heartburn in non-erosive GERD, different dosing Clin2 heartburn in non-erosive GERD, Clin2 eosinophilic esophagitis
About:
Phathom Pharmaceuticals is dedicated to improving treatments for gastrointestinal (GI) diseases. They focus on developing innovative therapies for acid-related disorders like ulcers and heartburn. One key area of their research is the development of new proton pump inhibitors – a class of drugs that reduce stomach acid production. While there are existing PPIs on the market, Phathom is investigating more effective and potentially longer-lasting options. This could lead to improved patient outcomes and potentially reduce the need for frequent medication use.
© 2025 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com